SHL clinches UK brief for Abilify

Shire Health London has bagged a UK brief for Bristol-Myers Squibb and Otsuka's schizophrenia drug, Abilify.

The account had previously been held by Pope Woodhead for more than four years.

SHL said it was aiming to ‘put Abilify on the map' via media relations campaigns, as it battles products such as Lilly's Zyprexa and AstraZeneca's Seroquel.

SHL director of operations Sophie Stannard leads a four-strong agency account team on the campaign.

The company's sister agency, Shire Health International, bagged the pan-European account for Abilify earlier this summer (PRWeek, 30 June).

SHL's contract-clinching meeting at BMS's Uxbridge offices was disrupted by an unrelated animal-rights protest at the site. This delayed the team's presentation for around 90 minutes.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in